Elisabetta Bugianesi, MD, PhD, is professor in the Division of Gastroenterology, Department of Medical Sciences, at the University of Torino, Italy.

Dr. Bugianesi is an internationally acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years experience in the field. She has made a particular impact with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, including the NAFLD Fibrosis score (currently recommended by the EASL-EASD-EASO Clinical practice Guidelines on NAFLD) and the involvement in several trials for the treatment of NAFLD/NASH.

She has been national PI of major EU funded research consortia: Fatty Liver: Inhibition of Progression (FLIP) (2010-2013), ‘EPoS’ Elucidating Pathways of Steatohepatitis (2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (IMI2, 2017-2022). As clinician, she is a practicing Hepatologist based at the GI Division of the University Hospital “Città della Salute e della Scienza of Torino”, Italy, where she is the lead physician for the Hepatology Outpatient Clinic and the Head of the Gastro-hepatology Laboratory. Her contribution to science is testified by over 200 publications, an H Index = 59, N. Citations = 19856 (Scopus).

‍